2 citations
,
March 2015 in “Hepatitis Monthly” This case report identified dystrophic anagen effluvium as a previously unreported dermatological side effect of PEG-INF-α-2a/RBV combination therapy in a patient with chronic hepatitis C infection.
6 citations
,
October 2016 in “Journal of Chemotherapy” This case report describes a rare instance of alopecia universalis occurring eight weeks after discontinuing pegylated interferon α and ribavirin therapy, highlighting the need for awareness among healthcare providers.
January 2014 in “대한피부과학회지” This case study in a hepatitis B patient observed that pegylated interferon alpha2a treatment may induce localized alopecia areata, which appeared to correlate with treatment administration and discontinuation.
1 citations
,
January 2014 in “Hair therapy & transplantation” This case study reports the first extensively interpreted instance of dystrophic telogen effluvium potentially linked to pegylated interferon and ribavirin therapy for chronic hepatitis C, characterized through clinical and trichogram analysis.
39 citations
,
January 2008 in “World Journal of Gastroenterology” This report documents the first known case of acute inflammatory demyelinating polyneuropathy potentially linked to pegylated interferon-alpha 2a in a woman undergoing treatment for chronic hepatitis C.
